Charles River to acquire Frontage bioanalysis operations for $470 million
Charles River Laboratories agreed to buy Frontage's bioanalysis and DMPK operations in Pennsylvania, adding clinical laboratory capacity and about 340 employees to its drug-development services platform.
Charles River Laboratories (NYSE: CRL) announced on November 9, 2026 that it had entered definitive agreements to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash, subject to customary closing adjustments.
The transaction includes additional payments of up to $75 million contingent on future performance. Charles River expects to close during the first half of 2027, subject to required shareholder and regulatory approvals and other customary closing conditions.
The assets comprise two sites providing bioanalysis, biomarker, and drug metabolism and pharmacokinetics (DMPK) testing for large and small molecules, primarily supporting biopharmaceutical development programs. They also include a CLIA-certified central laboratory, approximately 150,000 square feet of facilities, and about 340 employees.
Charles River said the acquisition will expand its clinical bioanalysis presence and complement its preclinical capabilities, particularly in biologics and complex modalities. The company said about 15% of its bioanalysis revenue currently comes from clinical-phase testing, so the acquired operations could strengthen continuity from early research through clinical development.
The company framed the transaction as part of its Pathway to Purpose strategy. The announcement does not yet change Charles River’s results: closing is expected in 2027 and remains subject to the stated approvals and conditions.
Initial price
$470M
cash
Contingent payments
up to $75M
performance-linked
Facility area
150,000 sq ft
two Exton sites
Employees
~340
in acquired operations
Sources
This story describes figures the company has published. It is for information only and is not investment advice or a recommendation to buy, sell or hold any security. Check the original filings before relying on any figure. Stoqly is not affiliated with the SEC or Charles River Laboratories.
